Trinity Biotech (NASDAQ:TRIB) Posts Quarterly Earnings Results

Trinity Biotech (NASDAQ:TRIB) released its earnings results on Tuesday. The company reported ($0.23) EPS for the quarter, Zacks reports.

Trinity Biotech Price Performance

Shares of TRIB opened at $0.57 on Wednesday. Trinity Biotech has a one year low of $0.50 and a one year high of $3.44. The stock’s fifty day moving average is $0.65 and its 200-day moving average is $0.75.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Trinity Biotech stock. Citadel Advisors LLC grew its holdings in shares of Trinity Biotech PLC (NASDAQ:TRIB) by 196.1% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 39,384 shares of the company’s stock after purchasing an additional 26,084 shares during the period. Citadel Advisors LLC owned approximately 1.10% of Trinity Biotech worth $41,000 at the end of the most recent reporting period. 78.97% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Separately, Weiss Ratings cut Trinity Biotech from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, May 8th. One research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Trinity Biotech currently has a consensus rating of “Reduce”.

Trinity Biotech Company Profile

Trinity Biotech plc is a global diagnostic healthcare company headquartered in Bray, Ireland. The firm specializes in the development, manufacture and marketing of in vitro diagnostic products aimed at the detection and management of chronic and infectious diseases. Its offerings are designed to deliver timely and accurate results for a range of healthcare settings, from central laboratories to point‐of‐care environments.

The company’s product portfolio includes a comprehensive array of assays and instrumentation.